Emergex looks forward to this important next step in the development of its novel T cell-priming Betacoronavirus candidate. NIAID is projected to cover the full cost of the Phase I clinical trial ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback